| Name: | Herma Renkema |
| Nationality: | Dutch |
| MSc education: | Medical Biology (Utrecht) |
| PhD education: | Biochemistry (U v Amsterdam) |
| Postdoc education: | Biochemistry (Amsterdam) HIV biology (Tampere, Finland) Mitochondrial biology (Nijmegen) |
| Current position: | Chief Scientific Officer, Khondrion |
| DCs: | Melisa Emel Ermert |
| Social media handles: | My LinkedIn Khondrion’s LinkedIn https://www.khondrion.com/ |
| Description of my lab’s work: | Khondrion’s development programme is based on more than 10 years of academic research, leveraging the increased understanding of the underlying mechanisms of primary mitochondrial disease in combination with the development of new cellular readouts. Khondrion’s drug development strategy is based on counteracting these cellular consequences to stall disease progression and to restore normal cellular function. Our lead compound sonlicromanol was developed based on a comprehensive screening programme after we had first determined the most direct disease-causing factors present across most of the now known pathogenic variants in genes causing mitochondrial diseases – i.e. reductive distress, oxidative distress and inflammation |
| Top 3 publications: | http://dx.doi.org/10.1038/s41598-018-24900-3 https://doi.org/10.1016/j.bbadis.2020.166062 https://doi.org/10.1038/s41598-020-79466-w |
| Favorite way to keep NAD levels high: | Biking to work |